"tVNS therapy in Comatose Patients"  has been a focus research area in recent years in collaboration with esteemed scientists from various countries. The Coma Symposium brought together notable experts, including Prof. Dr. Halil Özcan, Head of the Psychiatry Department at Erzurum Atatürk University, Prof. Dr. Arshad Majid, Head of Neuroscience and Cerebrovascular Neurology at the University of Sheffield, UK, Prof. Armin Bolz, the scientist who has been developing of the patented tVNS technology from Germany, and Selin Erdoğan Gezen, Global Clinical Director at tVNS Health Gmbh. The symposium hosted the discussions on the use of tVNS in comatose patients, sharing clinical experiences, and exploring the future of this therapy. The meeting was held on November 14-15th, under the organization of the Akogo Foundation, committed to providing care at the highest international standards, employing advanced diagnostic tools and neurorehabilitation techniques, in two dedicated "Alarm Clock" Clinics, the first rehabilitation centers for children and adults, in Poland. The event was a highly productive scientific meeting where the use of tVNS in comatose patients across different countries was discussed, patient grou ps who has the potential to benefit from the therapy were identified, and future scientific collaborations and studies were initiated. Sessions also featured case reports from Turkey by esteemed doctors Assoc. Prof. Dr. Burcu Polat and Prof. Dr. Ercan Gürses , highlighting treatments applied to hypoxic patients. These sessions provided inspiration for future treatment protocols. In the coming days, we look forward to sharing the results of a clinical study on the application of tVNS therapy, with the hope that it will inspire and bring new possibilities. We remain committed to offering hope to patients considered untreatable through non-invasive, scientifically supported therapies. Our deepest gratitude goes to our esteemed doctors and scientists for their invaluable contributions to these efforts. A special thank you to Fundacja Ewy Błaszczyk Akogo? for hosting this impactful event and fostering collaboration to advance pediatric care. Together, we’re working towards brighter possibilities. Source: https://www.akogo.pl/pl/aktualnosci/budzik-dla-dzieci/nauka-nie-spi #coma #tvns #vagusnerve #vagusnervestimulation #vnstherapy #vagusnerve #comatose #akogo #stroke #stroketreatment

Zeliha Korkmaz, the mother of 7-year-old Oğuzhan, who battles resistant epilepsy and was diagnosed with Dravet syndrome at 4.5 months old, recently shared their transformative journey with tVNS. Oğuzhan endured numerous hospitalizations due to refractory seizures, even undergoing a ketogenic diet that eventually proved ineffective. Following his physician's recommendation, Oğuzhan began using tVNS in January 2022. Since then, the positive impact on his life has been remarkable — experiencing extended seizure-free periods, enhanced cognitive abilities, and an overall improved quality of life. At tVNS, we strive to contribute to a better world for human life by evolving treatments to meet the changing needs of our dynamic world.

The "tVNS Special Issue", has been published in the "Journal Autonomic Neuroscience", the official journal of the International Society for Autonomic Neuroscience, published by Elsevier. We are proud to design the future of neuroscience and to be the pioneer of the medical technologies. Below are the titles of the tVNS Clinical Studies and articles in the journal. Link is below: 1. tVNS in the treatment of drug-resistant epilepsy 2. Cardiovascular responses to low-level transcutaneous vagus nerve stimulation 3. Electrical vagus nerve stimulation as a prophylaxis for SIRS and postoperative ileus 4. tVNS as a potential therapeutic application for neurodegenerative disorders – A focus on dysautonomia in Parkinson's disease 5. tVNS in the management of headache and pain 6. Brain plasticity and vagus nerve stimulation 7. tVNS for the treatment of postural tachycardia syndrome 8. Functional anatomy of the vagus system – Emphasis on the somato-visceral interface 9. Effects of tVNS on cardiovascular autonomic control in health and disease 10. tVNS and heart rate variability: Analysis of parameters and targets 11. Current challenges in reliably targeting the noradrenergic locus coeruleus using transcutaneous auricular vagus nerve stimulation (taVNS) 12. The LC-NE system as a potential target for neuromodulation to ameliorate non-motor symptoms in Parkinson's disease 13. Vagus nerve afferent stimulation: Projection into the brain, reflexive physiological, perceptual, and behavioral responses, and clinical relevance 14. Transcutaneous vagus nerve stimulation (tVNS) in stroke: the evidence, challenges and future directions 15. t-VNS to treat disorders of behaviour in Prader-Willi Syndrome and in people with other neurodevelopmental conditions 16. Technical aspects and future approaches in transcutaneous vagus nerve stimulation (tVNS) 17. A two-week course of transcutaneous vagal nerve stimulation improves global sleep: Findings from a randomised trial in community-dwelling adults https://www.sciencedirect.com/journal/autonomic-neuroscience/special-issue/10DBND1B8HC

PD. Dr. Ranni von Wrede and Dr. Pukrowski, leading epileptologists from the University of Bonn, discuss the concept of Transcutaneous Vagus Nerve Stimulation (tVNS), an effective method for epilepsy treatment. Based on her experience in tVNS and Vagus Nerve Stimulation for epilepsy, Dr. Wrede explains this method in detail, which is simpler and more effective compared to traditional methods. General overview is provided about the device's usage, side effects, and treatment process. Source: https://lnkd.in/eP4Fkfrh

Pediatric neurology specialist Associate Professor Dr. Barış Ekici shares his insights and experiences with transcutaneous vagus nerve stimulation therapy: "Vagus stimulation is a technique that works on stimulating the vagus nerve. It has been an approved treatment for epilepsy since 1997 and for resistant depression since 2005. Vagus stimulation creates an impulse that travels from the brainstem to higher centers in the brain, carrying an electrical signal from the brainstem to the amygdala, hippocampus, and frontal lobe. Initially, devices placed on the vagus nerve through surgery were used. The human ear has an extensive network of nerve stimuli. Specifically, there are branches of the vagus nerve that intensely travel to the brain in the concha, the hollow part of our ear. Using this device, we deliver some repetitive stimuli at microampere levels and microsecond durations to the ear, thereby carrying a signal from the brainstem to the brain. Vagus stimulation alters brain chemicals and activates the GABAergic system, which we know functions poorly in children with autism. Studies have shown that following vagus stimulation, GABAergic metabolites increase, and glutamate decreases in brain fluid. It also stimulates and regulates the serotonergic and noradrenergic systems. Additionally, it calms the brain and reduces neuroinflammation. With vagus stimulation, we expect children with autism to be calmer, more focused, have improved sleep quality, reduced obsessions, and increased speech. The feedback from our patients aligns with these expectations. Thanks to state-of-the-art devices, we now have the opportunity to apply this method to children via the ear, and we begin to see positive effects after a month of stimulation. The good aspect is that after planning the stimulation according to the child's EEG, it is a method that the family can apply at home on their own. We do not see many side effects. Mild side effects such as redness in the ear and occasional headaches are reported. For now, our patients are satisfied with vagus stimulation. We generally receive feedback from parents that their child is calmer, more focused, and has increased speech. When you increase the activity in children with autism, you lose functionality. Therefore, I believe that vagus stimulation, which works from the brainstem to the brain and helps the child find their balance in a calming manner, is very suitable for children with autism."

Discover the inspiring journey of Elena, a young girl with Aicardi syndrome and drug-resistant epilepsy, and the positive impact of tVNS on her life. The mother of Elena, recounts their journey with their daughter, who began grappling with epilepsy at the tender age of four months. Faced with the complexity of drug-resistant epilepsy and numerous failed medication attempts, the family turned to a tVNS device in September 2022. Over the course of eight months, they observed notable advancements in seizure management, with occasional seizure-free days providing a glimmer of relief. The speaker expresses appreciation for the positive impact on their daughter's life, citing improvements in cognitive skills, communication, and motor functions. While acknowledging the ongoing challenges posed by epilepsy, the testimonial highlights the perceived contribution of the tVNS device to enhancing the overall quality of life for their daughter.

Inspiring Insights from Prof. Dr. Halil Özcan on Vagus Nerve Stimulation🌟 It's been two months since our enlightening conversation with Prof. Dr. Halil Özcan, Head of the Department of Psychiatry at Atatürk University in Erzurum, Turkey. Prof. Özcan has been at the forefront of numerous successful treatments with our tVNS® Vagus Nerve Stimulation Device since 2021. During our discussion, Prof. Özcan shared invaluable experiences and insights into vagal nerve stimulation and its diverse applications across various indications. He recounted remarkable stories of recovery, notably highlighting exceptional improvements in coma patients after receiving treatment. With over two decades of research in clinical studies worldwide, Prof. Özcan's pioneering work has paved the way for the use of vagus nerve stimulation in treating conditions such as depression, anxiety disorders, and sleep problems, yielding positive outcomes at Neuromodulation centers. His positive experiences with chronic migraine and tinnitus patients offer hope for millions facing similar challenges, showcasing the potential of vagal nerve stimulation to revolutionize healthcare as a low side-effect option for various conditions. We extend our heartfelt gratitude to Prof. Dr. Halil Özcan and Atatürk University for their invaluable contributions to advancing science and restoring countless patients to a new lease on life. We eagerly anticipate future collaborations and groundbreaking studies. For more insights, visit our website and YouTube channel, and feel free to reach out for treatment protocols and clinical details.

We are very happy to contribute to the recovery of a 30-year-old coma patient. Our doctor Prof. Halil Özcan, who has significant progress on tVNS clinical studies, tells the story of a miraculous treatment that took place in the Neuromodulation department of Erzurum Atatürk University: "A 30-year-old woman, teacher, was referred to our hospital from the private hospital where she gave birth 15 months ago due to postpartum sinus vein thrombosis and cerebral hemorrhage (in the right temporal region), with glasgow coma score 5, unconsciousness and complete paralysis. After 1 month in the intensive care unit, in the fourth month of his stay in the palliative care unit, the patient was consulted to a psychiatrist, whose general condition was poor, eyes were spontaneously open, but had an unresponsive glasgow coma score of 7 and spontaneous crying. At that time, the patient was fed with a duodenal tube and had spontaneous breathing. The patient, who had epileptic seizures twice, was therefore using valproic acid 2000 mg and levetiracetam 3000 mg. She occasionally used various antibiotics, painkillers and proton pump inhibitors, and lotions for skin care, oral care, etc. A year ago, when the patient was first examined, no communication could be established, so the reason of crying could not be clarified. Escitalopram 10 mg was started as an antidepressant. Alprazolam 1 mg/day and pregabalin 2x25 mg/day were added to the treatment of the patient who did not respond to previous medication. In the meantime, it was reported to his family that there are patients in vegetative state and coma in the world, who have been treated with vagal nerve stimulation and obtained significant progress. The application was started after the family approval. Considering the limited available literature, we decided to use both transauricular vagus nerve stimulation (tvns) and transcranial direct current stimulation (tdcs) treatments together, as it was thought to be more beneficial. We used tVNS®-R from tVNS Technologies , 25 hertz continuous stimulation to the left ear cymba conchae region, 1-3 hours a day in the range of 100-3000 microamperes. And (tdcs -apex type A) 2 milliamper anode cathode close to the right temporal lobe. It was placed in the left orbitofrontal cortex and the application was made with continuous stimulation for 20 minutes. The application was planned to be 5 days a week (weekdays). In the 4th month of the treatment, we recommended to stop tVNS therapy, since no significant benefit was observed. However, the application was continued after family stated that they saw positive changes in the patient (as if she was looking at us, she understood what we were saying, etc.). In the 6th month of the treatment, spontaneous movements in the right leg of the patient and eye contact was observed and she tried to lift her leg. Therapy continued after this pleasing development. One month later, the patient made a complete sentence (she said, 'Daddy, will you give me coffee?', they had used to drink coffee with her father before). After this amazing progress, the patient's cognitive and speech improved day by day. Finally, the patient's left leg and head began to move. Glasgow coma score become 15 full points. As of now, the patient's speech is mildly dysarthric, but she can understand what is being said and can easily give appropriate answers. The patient's treatment continues in the palliative unit after 15th month in our hospital. tVNS and tdcs therapies have completed 1 year and we continue for more improvement."

Elevate your health journey and discover a medication-free, low side effect and non-invasive therapy option for the treatment of brain diseases. tVNS® is a medical device for the treatment of symptoms of sympathovagal imbalance and was specially developed for patients who are not free of symptoms despite drug therapy. tVNS® stimulates the branch of the vagus nerve in the auricle through the skin with gentle electrical impulses. It is applied with a specially designed ear electrode up to 4 hours per day. Embarked upon by thousands, tVNS® therapy stands out as a game-changer, offering individuals a transformative and gentle journey towards a better quality of life with remarkable effectiveness and minimal side effects. Be a part of your succes story.